Trade Desk, Inc.

This signal appears incongruous: Eventide, a values-based investor with deep biotech expertise, initiated a $5.2M position in Trade Desk (TTD), a programmatic advertising platform with no direct biotech operations. Either this represents portfolio diversification into adjacent health-tech infrastructure, or it reflects confidence in TTD's expansion into healthcare ad networks—a sector benefiting from increased digital health spend post-pandemic. The catalyst and strategic rationale warrant clarification, as it diverges materially from Eventide's core biotech thesis.